BioNTech's new crown mRNA vaccine may be approved in China before July, and the introduction of many foreign vaccines into vaccines is progressing slowly

On April 28, local time, Ugur Sahin, the founder and CEO of the German biotechnology company BioNTech, attended an online meeting of the German Association of Foreign Journalists, saying that the company's new mRNA vaccine BNT162b2 might be available in China before July.

Earlier, the English version of The Wall Street Journal and the Global Times quoted sources as reporting that China is likely to approve the new crown vaccine jointly developed by Germany's BioNTech and China's Fosun Pharma before July.

After the second dose of BNT162b2 vaccine, the serum of the SARS-CoV-2 variant strain was neutralized

BNT162b2 is an mRNA new coronavirus vaccine that carries the genetic information of the virus.

Early rate reductions of SARS-CoV-2 infection andCOVID-19in BNT162b2 vaccine recipients, Published Online February 18, 2021 https://doi.

The research team observed the results of more than 9,000 medical staff vaccinated in Israel and found that within 15 to 28 days after the first dose of the vaccine, the number of people with symptoms of the new crown decreased by 85%.

According to Metz Medical, the Phase II clinical trial of the new crown mRNA vaccine BNT162b2, which was launched on November 24 last year, is nearing completion.

Hui Aimin, Senior Vice President of Fosun Pharma, President and Chief Medical Officer of Global R&D Center, once stated that as an important part of global R&D, the second phase clinical study of BNT162b2 in China will not only provide key data for the vaccine’s launch in China, but also It may also play a positive role in the widespread promotion and use of the vaccine in other peoples around the world, especially in other Asian countries and regions.

Fosun Pharma Announcement

The Hong Kong Special Administrative Region Government approved BNT162b2 for emergency use in Hong Kong on January 25 this year.

It is understood that the introduction of several foreign vaccines has been slow

Hualan Biology issued an announcement on the evening of April 19 that the Russian HV company transferred the Sputnik-V (Satellite V vaccine) new crown vaccine 5L/200L production technology to Hualan Vaccine, a subsidiary of Hualan Biology.

The Sputnik-V (Satellite V Vaccine) Covid-19 vaccine was developed by the Gammaler Institute and is the world's first registered vaccine based on a well-researched human adenovirus vector platform.

In November 2020, Top Ridge Pharma Limited, a wholly-owned subsidiary of Tibet Pharmaceuticals, had cooperated with Russian Human Vaccine to obtain the registration, development, production, import or commercialization of Sputnik-V adenovirus vector vaccine in mainland China and Hong Kong, Macao and Taiwan.

However, the relevant announcement also pointed out that since Tibet Pharmaceuticals does not yet have the ability to develop and produce adenovirus vaccines, it will separately entrust a third party to carry out vaccine technology transfer and preliminary R&D and production in China.